< 1 minute read
May 9, 2023
OI338: Oral Insulin Analog Shows Ultralong Half-Life
OI338
oral, ultralong-acting insulin analog effective in Ph. IIa, hum. t1/2 ~3 d, 4% F dog albumin-binding motif + reduced endocytosis J. Med. Chem., Dec. 28, 2020 Novo Nordisk, Maaloev, DK